



Attorney Docket No.: 3469.224-US

GP/6524  
PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Rasmussen et al.

Serial No.: 09/189,028

Group Art Unit: 1652

Filed: November 10, 1998

Examiner: L. Hobbs

For: A Cellulase Preparation Comprising An Endoglucanase Enzyme

**CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)**

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

I hereby certify that the attached correspondence comprising:

1. Amendment Fee Transmittal (in duplicate)
2. Amendment

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Asst. Commissioner for Patents  
Washington, DC 20231

on December 7, 1999.

Gina Maldonado  
(name of person mailing paper)

*Gina Maldonado*  
(signature of person mailing paper)

RECEIVED  
TECH CENTER 1500/2900  
99 DEC 13 AM 8:04

*B*



Attorney Docket No.: 3469.224-US

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Rasmussen et al.

Serial No.: 09/189,028

Group Art Unit: 1652

Filed: November 10, 1998

Examiner: L. Hobbs

For: A Cellulase Preparation Comprising An Endoglucanase Enzyme

**AMENDMENT FEE TRANSMITTAL**

Assistant Commissioner for Patents

Washington, DC 20231

Sir:

Transmitted herewith is an Amendment for the above-identified application in response to the Office Action mailed August 31, 1999.

It is respectfully requested that the time for response to the Office Action dated August 31, 1999 be extended for a period of 1 month from November 30, 1999 to December 31, 1999. The required fee for the extension is estimated to be \$110.

The fee for claims has been calculated as shown below:

Total:  $21 - 20 = 1 \times 18 = \$18$

Independent:  $3 - 3 = 0 \times 78 = \$0$

Total additional fee for claims required is \$18.

Please charge the required extension and claims fees, estimated to be \$128, to Novo Nordisk of North America, Inc., Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: December 7, 1999

Reza Green, Reg. No. 38,475  
Novo Nordisk of North America, Inc.  
405 Lexington Avenue, Suite 6400  
New York, NY 10174-6401  
(212) 867-0123

99 DEC 13 AM 8:04

RECEIVED  
TECH CENTER 1500/2900



Attorney Pocket No.: 3469.224-US

PATENT

6B  
LP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Rasmussen et al.

Serial No.: 09/189,028

Group Art Unit: 1652

Filed: November 10, 1998

Examiner: L. Hobbs

For: A Cellulase Preparation Comprising an Endoglucanase Enzyme

AMENDMENT

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

In response to the Office Action mailed August 31, 1999, kindly amend the above-identified application as set forth below.

IN THE CLAIMS:

Cancel claims 32-49 without prejudice or disclaimer.

Add new claims 50-70 reading as follows:

~~50~~. A DNA construct encoding an endoglucanase enzyme, wherein said construct has a sequence selected from the group consisting of:

(a) the sequence of SEQ ID NO:1; and

(b) a sequence which hybridizes to the sequence of SEQ ID NO:1 at 40°C in 20% formamide-50 mM sodium phosphate pH 6.8.—

~~51~~. A DNA construct as defined in claim ~~50~~, wherein said sequence is derived from *Humicola*.—

64

12/09/1999 SLUANG 00000151 14144 09189028  
01 FC:115 110.00 CH  
02 FC:103 18.00 CH

8